SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing a sharp sell-off following the announcement that Marvell cancelled purchase orders due to an alleged breach of confidentiality triggered by recent public comments from the company's CFO. While the community remains deeply divided between those calling the stock a fundamental failure and others who view the dip as a tactical buying opportunity, the primary concern is the potential erosion of trust with future hyperscale partners.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as investors weigh strong AI and automotive growth potential against near-term headwinds like supply chain constraints and cautious analyst sentiment. The stock is a primary focus for the community, which remains divided on whether the current price represents a buying opportunity or a deeper structural decline.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as they await topline Phase 3 data from the HAELO trial, which the community sees as a potential validation for their in vivo CRISPR platform. Traders are actively debating the high short interest and the stock's susceptibility to a squeeze, with many weighing the clinical promise of a functional HAE cure against the broader volatility affecting the biotech sector.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is experiencing significant bullish momentum driven by heavy short interest and mounting anticipation for its acquisition of Northern Data, which effectively expands its cloud and GPU infrastructure. The community is actively discussing a potential short squeeze, citing record-high short interest and strong backing from strategic partner Tether as catalysts for a potential rally.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing significant market movement driven by speculative interest in its shift toward custom AI chip design and high-performance server CPUs. Community discussions are split between euphoria over its long-term potential as an AI infrastructure backbone and intense debate regarding its valuation, with many traders actively debating the merits of aggressive shorting versus holding for a potential parabolic breakout.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is drawing significant investor interest as it approaches a high-profile oral presentation of pancreatic cancer data at Digestive Disease Week, which the community views as a critical catalyst for the stock. Traders are actively accumulating shares, citing strong scientific momentum and the company's progress in expanding global clinical trials.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is gaining significant momentum as investors digest a new share buyback program and the upcoming elimination of pattern day trading (PDT) restrictions. The community is actively debating the stock's valuation relative to its growth potential, with many discussing potential short squeeze setups and comparing its market positioning to peers like Robinhood.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares is experiencing massive volatility and bullish momentum driven by a strong semiconductor sector rally, fueled by earnings optimism and ongoing AI infrastructure spending. Investors are actively debating whether the current parabolic price action signifies a sustainable super-cycle or a speculative bubble, leading to intense sentiment clashes between bullish 'diamond hands' and traders betting on a sharp mean reversion.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is currently seeing significant investor attention driven by positive Phase 3 acne data and the potential for its FASN inhibitor denifanstat as a cornerstone MASH treatment. The community is actively debating the company's valuation, the strategic shift toward combination therapies, and the high probability of a future buyout given the surge in M&A activity within the metabolic disease sector.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is generating significant investor buzz as it makes its market debut, with the community highlighting its strategic backing from major players like Amazon and Dow to address the surging energy demands of AI data centers. Traders are actively debating the company's valuation and long-term potential compared to other modular nuclear reactor peers, fueled by high initial demand and its positioning as a key player in the clean energy infrastructure space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes...

Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm...

Benitec Biopharma Limited (NASDAQ:BNTC) Receives Average Recommendation of "Moderate Buy" from Brokerages

Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold rec...

Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50 Day Moving Average - What's Next?

Benitec Biopharma (NASDAQ:BNTC) Stock Price Passes Above Fifty Day Moving Average - Time to Sell...

Benitec Biopharma Reports Promising Interim Results For BB-301 Gene Therapy In OPMD Trial

(RTTNews) - Benitec Biopharma Inc. (BNTC) on Monday, announced encouraging interim results from its Phase 1b/2a clinical study evaluating BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy...

Benitec Biopharma's (BNTC) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $32.00 price target on shares of Benitec Biopharma in a research report on Monday...

HC Wainwright Issues Optimistic Forecast for BNTC Earnings

Benitec Biopharma Limited (NASDAQ:BNTC - Free Report) - Equities researchers at HC Wainwright boosted their Q3 2026 earnings per share estimates for Benitec Biopharma in a research report issued on...

Analysts Issue Forecasts for BNTC Q1 Earnings

Benitec Biopharma Limited (NASDAQ:BNTC - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Benitec Biopharma in a research report...

Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Rating of "Moderate Buy" from Brokerages

Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat.com reports. One...

Benitec Biopharma (NASDAQ:BNTC) Shares Cross Below 50-Day Moving Average - Here's Why

Benitec Biopharma (NASDAQ:BNTC) Share Price Passes Below 50-Day Moving Average - Time to Sell...

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firm's proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.28	--	--	N/A
Q2 '26	-$0.22	-$0.26	-16.42%	MISSED
Q1 '26	-$0.45	-$0.22	51.11%	BEAT
Q4 '25	-$0.31	-$0.39	-25.81%	MISSED
Q3 '25	-$0.35	-$0.24	31.10%	BEAT

BNTC
Benitec Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '26

Historical Earnings

Latest BNTC News

BNTCBenitec Biopharma Inc